XASE · KAPA
+10.29% · +$0.0900 · Vol 5.8M
Market closed · last close 4:00 PM ET · price as of 20:00:00 ET
Kairos Pharma, Ltd.

Kairos Pharma, Ltd.

PHARMACEUTICAL PREPARATIONS
$0.9595
Card
Relationship Map

Follow $KAPA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $KAPA by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
KAPA
Kairos Pharma, Ltd.
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

54/ 100
Veridion Score
Middle range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KAPA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KAPA catalysts
About Kairos Pharma, Ltd.
PHARMACEUTICAL PREPARATIONS
Listed since
2024
Employees
1
Country
US

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.9300
Day high
$1.25
Day low
$0.9150
Previous close
$0.8700
52W high
$9.24
-89.62% from high
52W low
$0.8700
1% of range
Market cap
$2.9M
Beta
1.65
Shares out
3.4M
Volume
5.8M
9.05× rel vol
Avg volume
642.8K
VWAP
$1.06
Price history computed in-house
1W
-38.49%
1M
-42.20%
3M
-61.14%
1Y
-89.62%
YTD
-80.69%
SMA 50 $1.88 · below
SMA 200 $3.44 · below
52W position 1%

KAPA overview

Veridion Score
54
Registered · 2026-10-08
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KAPA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KAPA Form 4 filings
Public disclosures

Congress activity in KAPA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

KAPA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KAPA in this window.
Lobbying spend

KAPA lobbying filings, year to date.

Registered lobbying filings matched to Kairos Pharma, Ltd..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KAPA in this window.
Loading news for KAPA
Analyst ratings
Sovereign unlock shows live analyst consensus for KAPA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.